Defects in Ikaros expression as well as the shift in T cell immune balance in the spontaneous pancreatic cancer mice, provide evidence that Ikaros may indeed have clinical relevance in regulating effector and regulatory T cell immune responses in pancreatic cancer hosts. This evidence concerns the gene IKZF1 and pancreatic neoplasm.